ROC curve analysis showed that the addition of IGFBP‐2 and ‐3 biomarkers to a preoperative reference model comprising age, sex, and clinical tumor stage improved the discriminatory ability for prediction of LNM (+10.0%, P < 0.001), pT3/4 disease (+1.3%, P = 0.024), and any NOCD (+2.4%, P = 0.003). This evidence concerns the gene IGFBP2 and neoplasm.